Results 231 to 240 of about 47,774 (288)

Weaknesses out of strength: PNA against the penicillin-binding proteins. [PDF]

Mol Ther Nucleic Acids
Wdowiak M.
europepmc   +1 more source

The hsa_circ_0070354/miR‐4322/RAB3B Axis Facilitates the Carcinogenesis and Development of Non‐Small Cell Lung Cancer (NSCLC)

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background Circular RNA (hsa_circ_0070354), also known as circPTPN13, was demonstrated in our previous study that it can be used as a biomarker for diagnosing non‐small cell lung cancer (NSCLC). However, the mechanism of its role in the occurrence and development of NSCLC has not been investigated.
Yuejiao Huang, Shiyi Qin, Yu Zhang, Xinliang Gu, Ming Zheng, Guojie Ling, Lei Yang, Shaoqing Ju   +7 more
wiley   +1 more source

Systemic distribution of tricyclo-DNA antisense oligonucleotide following intratracheal instillation in the mouse. [PDF]

NAR Mol Med
Laurent J, Deramaudt TB, Cloix R, Robin V, Beley C, Garcia L, Bonay M.   +6 more
europepmc   +1 more source

Hepatocyte growth factor/c‐Met signaling axis in human diseases: Mechanistic insights and therapeutic potential

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun, Hao Shu, Qian Zhang, Jishan Zheng, Yunyan Ma, Dengwang Chen, Jidong Zhang, Tao Song   +7 more
wiley   +1 more source

Enhanced liver-targeted delivery with ribofuranose-based GalNAc conjugates. [PDF]

Mol Ther Nucleic Acids
Pradeep SP, Ruchi R, Bahal R.
europepmc   +1 more source

Progress of Immunotherapies in Parkinson's Disease

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Parkinson's disease (PD) is caused by an immune disorder triggered by α‐synuclein, leading to a persistent neuroinflammatory cycle that drives the disease from non‐motor symptoms to the motor stage. Second, it presents active and passive immunotherapy strategies targeting α‐synuclein and their potential in slowing down the disease progression.
Yong Peng, Xu‐hui Kang, Shun‐yu Yao, Xiuli Zhang, Sugimoto Kazuo, Jia Liu, Miao‐qiao Du, Lan‐xin Lin, Dai‐yi Jiang, Quan Chen, Hong Jin   +10 more
wiley   +1 more source

Targeting Non-Coding RNAs as a Potential Therapeutic and Delivery Strategy Against Neurodegenerative Diseases. [PDF]

Int J Mol Sci
Bougea A.
europepmc   +1 more source

Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA. [PDF]

Genes (Basel)
Yesbek Kaymaz A, Bora-Akoğlu G, Erdem Yurter H, Grunseich C.   +3 more
europepmc   +1 more source

MicroRNAs in cancer: biogenesis, biomarkers and therapeutic strategies. [PDF]

Front Med (Lausanne)
Rawat N, Babu N, Hussain A, Panwar AS.
europepmc   +1 more source

RNA therapies are delivering as therapies for neuromuscular dystrophy patients: Editorial for the special issue on RNA therapies in Journal of Neuromuscular Diseases. [PDF]

J Neuromuscul Dis
Aartsma-Rus A, Takeda S.
europepmc   +1 more source